کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5524084 | 1546241 | 2017 | 6 صفحه PDF | دانلود رایگان |
- We observed comparable outcomes of busulfan/fludarabine versus fludarabine/400âcGy total body irradiation conditioning.
- We observed fewer red blood cell transfusions and longer time to platelet recovery with busulfan/fludarabine than fludarabine/total body irradiation
- This study demonstrated comparable quality of life between busulfan/fludarabine and fludarabine/total body irradiation conditioning for acute myeloid leukemia/ myelodysplastic syndrome
Allogeneic hematopoietic cell transplantation conditioning regimen intensity has varied for patients with acute myeloid leukemia and myelodysplastic syndrome. A comparative effectiveness analysis was performed to assess outcomes of busulfan and fludarabine (BuFlu) versus those of fludarabine and 400âcGy total body irradiation (FluTBI) conditioning. Thirty-three subjects received BuFlu and 38 received FluTBI. The BuFlu group received more red blood cell transfusions (Pâ=â.02) and had a longer time to platelet recovery (Pâ=â.004). There were no differences between the regimens regarding incidence of acute or chronic graft-versus-host disease (GVHD), quality of life, or 2-year outcome estimates for relapse (48; 95% confidence interval [CI], 30 to 64 and 50; 95% CI, 33 to 65), nonrelapse mortality (29; 95% CI, 14 to 45 and 29; 95% CI, 15 to 44), relapse-free survival (27; 95% CI, 13 to 43 and 29; 95% CI, 16 to 44), and overall survival (35; 95% CI, 19 to 51; and 37; 95% CI, 22 to 52), respectively. These comparable outcomes have implications for health care resource utilization. Future prospective investigation comparing these regimens with larger patient cohorts and additional strategies to prevent relapse and limit toxicities as well as cost-effectiveness analyses are warranted.
Journal: Biology of Blood and Marrow Transplantation - Volume 23, Issue 5, May 2017, Pages 776-781